Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Agouron Pharmaceuticals
• Treatments: Anti-Retroviral Agents; Capravirine; Lamivudine; Lamivudine, zidovudine drug combination; Nelfinavir; Zidovudine

Criteria

Inclusion Criteria

Patients may be eligible if they:

• Are HIV-positive.

• Are at least 18 years old.

• Have a CD4 cell count of more than 50 cells/mm3.

• Have an HIV level of more than 5000 copies/ml.

Exclusion Criteria

Patients will not be eligible if they:

• Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.

• Have taken an experimental drug within 28 days of study entry.